알림

Candel Therapeutics Inc. (CADL)

NasdaqGM: CADL · 실시간 가격 · USD

12.05

-0.11 (-0.90%)

종가 기준: Aug 18, 2026, 3:59 PM

-0.90% (1D)

매수호가	7.49
시가총액	922.05M
매출 (ttm)	n/a
순이익 (ttm)	-88.53M
베타	-0.50
EPS (ttm)	-1.47
P/E (ttm)	n/a
선행 P/E	-19.28
P/B (ttm)	7.27
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

매도호가	13.51
거래량	786,293
평균 거래량 (20일)	1,647,104
시가	11.92
전일 종가	12.16
일중 범위	11.77 - 12.15
52주 범위	4.35 - 12.48
애널리스트	Strong Buy
목표주가	22.5 (86.72%)
배당	n/a
배당락일	n/a

CADL 소개

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develo...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 27, 2021

직원 수 55

상장 거래소 NasdaqGM

티커 CADL

웹사이트 https://www.candeltx.com

전체 기업 정보

재무 실적

2025년 Candel Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -38.18M로, -30.8% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 8명의 투자의견을 종합하면 CADL 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 22.5로, 최근 주가 대비 86.72% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Candel Therapeutics가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.36 예상치 하회 -0.13, 및 -80.00% 전년 대비 감소.

다음 실적 발표

Candel Therapeutics Inc.의 실적 발표 예정일은 Nov 12, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

5일 전 · Stocktwits

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4

If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product.

6일 전 · Stocktwits

CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity

Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.

6일 전 · MarketBeat

Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up

Candel Therapeutics (NASDAQ:CADL) is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief S...

1개월 전 · Stocktwits

CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’

Candel Therapeutics announced the initiation of a Phase 3 trial evaluating lead therapy CAN-2409 in advanced non-small cell lung cancer patients.

1개월 전 · Exec Edge

Candel Therapeutics Designates Mark Sims as CCO

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Gl...

2 페이지 중 1

Candel Therapeutics Inc. (CADL)